Androgen group calls for ethical investigation of JAMA
The Androgen Study Group submitted a formal request to the Journal Oversight Committee for investigation of the Journal of the American Medical Association due to its acceptance of Vigen and colleagues’ study that called into question the cardiovascular safety of testosterone.
“The Androgen Study Group wishes to register with the Committee our grave concern that JAMA has violated accepted standards of medical journal ethics and editorial integrity,” the authors of the complaint wrote.
The Androgen Study Group details 13 reasons they find publication and promotion of this article to be worthy of ethical investigation.
“This article is a mess and JAMA has behaved badly,” the group wrote. “We believe that with regard to this article, JAMA has failed in its review process, its selection of this article for publication, its promotion of this article, its post-publication response to important revealed errors and in its editorial ethics and integrity.”
In a previous interview with Endocrine Today, P. Michael Ho, MD, the corresponding author for Vigen et al., said, “We stand by our results. ... As clearly stated in the manuscript, this was an observational study and did not conclude causality.”
The Food and Drug Administration has scheduled a hearing on testosterone therapy for September.
For more information: Complaint to Journal Oversight Committee at JAMA